Get started
Author

Alex T. Larsson

Observed names: Alex Larsson, Alex T Larsson
ORCID: 0000-0002-1350-8271
Observed ORCID: 0000-0002-1350-8271
OpenAlex ID: A5084774714
Sleeping Beauty Insertional Mutagenesis Reveals Important Genetic Drivers of Central Nervous System Embryonal Tumors
2019 · Pauline J. Beckmann, Jon D. Larson, et al. · Cancer Research · 50
PDF
CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors
2023 · Jiawan Wang, Ana Calizo, et al. · Science Advances · 33
PDF
PLX3397 treatment inhibits constitutive CSF1R-induced oncogenic ERK signaling, reduces tumor growth, and metastatic burden in osteosarcoma
2020 · Branden A. Smeester, Nicholas J. Slipek, et al. · Bone · 32
Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology
2023 · Alex T Larsson, Himanshi Bhatia, et al. · Neuro-Oncology · 19
PDF
Implication of ZNF217 in Accelerating Tumor Development and Therapeutically Targeting ZNF217-Induced PI3K–AKT Signaling for the Treatment of Metastatic Osteosarcoma
2020 · Branden A. Smeester, Garrett M. Draper, et al. · Molecular Cancer Therapeutics · 15
Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors
2025 · Kyle B. Williams, Alex T. Larsson, et al. · Molecular Cancer Therapeutics · 9
Multiomic analyses reveal new targets of polycomb repressor complex 2 in Schwann lineage cells and malignant peripheral nerve sheath tumors
2024 · Minu M Bhunia, Christopher M Stehn, et al. · Neuro-Oncology Advances · 4
PDF
Sleeping Beauty mutagenesis identifies BACH2 and other regulators of CD8 + T-cell exhaustion, persistence in vivo, and CAR-T cell function under tumor-associated chronic antigen stimulation
2026 · Chang-Jung Lee, Alex T Larsson, et al. · Journal for ImmunoTherapy of Cancer · 1
Sleeping Beauty mutagenesis identifies BACH2 and other regulators of CD8 + T cell exhaustion, persistence in vivo , and CAR-T function under tumor-associated chronic antigen stimulation
2025 · Chang-Jung Lee, Alex T. Larsson, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 1
PDF
Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology
2022 · Himanshi Bhatia, Alex T. Larsson, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 1
PDF
Abstract 1121: Validation of FOXR2 and ARHGAP36 as oncogenes in medulloblastoma
2016 · Pauline Jackson, Alex Larsson, et al. · Cancer Research · 1
Biomarker-driven and gene-enhanced viral therapy for malignant peripheral nerve sheath tumor
2026 · Meghna Saxena, Love Li, et al. · bioRxiv (Cold Spring Harbor Laboratory)
PDF
Integrated ex vivo screening and transcriptomic profiling to prioritize drug combinations for rare cancers
2026 · Ritu C. Shah, Alex T. Larsson, et al. · bioRxiv (Cold Spring Harbor Laboratory)
PDF
Supplementary Figure 2 from Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors
2026 · Kyle B. Williams, Alex T. Larsson, et al.
Supplementary Figure 8 from Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors
2026 · Kyle B. Williams, Alex T. Larsson, et al.
Supplementary Figure 5 from Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors
2026 · Kyle B. Williams, Alex T. Larsson, et al.
Supplementary Figure 11 from Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors
2026 · Kyle B. Williams, Alex T. Larsson, et al.
Supplementary Table 2 from Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors
2026 · Kyle B. Williams, Alex T. Larsson, et al.
Data from Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors
2026 · Kyle B. Williams, Alex T. Larsson, et al.
Supplementary Figure 7 from Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors
2026 · Kyle B. Williams, Alex T. Larsson, et al.
Supplementary Table 4 from Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors
2026 · Kyle B. Williams, Alex T. Larsson, et al.
Supplementary Figure 12 from Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors
2026 · Kyle B. Williams, Alex T. Larsson, et al.
Supplementary Figure 6 from Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors
2026 · Kyle B. Williams, Alex T. Larsson, et al.
Supplementary Figure 4 from Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors
2026 · Kyle B. Williams, Alex T. Larsson, et al.
Supplementary Table 3 from Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors
2026 · Kyle B. Williams, Alex T. Larsson, et al.
Works count: 56
Citation count: 166
H-index: 6
I10-index: 5
Year
Topic
Type